Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 24, 2024
Antiandrogen Flutamide-Induced Restoration of miR-449 Expression Mitigates Functional Biomarkers Associated with Ovarian Cancer Risk.
Journal: medRxiv : the preprint server for health sciences
Published: March 11, 2024
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: September 04, 2023
NRF2 controls iron homeostasis and ferroptosis through HERC2 and VAMP8.
Journal: Science advances
Published: February 01, 2023
A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 07, 2022
Advances in Chemotherapy and Targeted Therapies in Endometrial Cancer.
Journal: Cancers
Published: August 29, 2022
Dissection of transcriptome dysregulation and immune characterization in women with germline BRCA1 mutation at single-cell resolution.
Journal: BMC medicine
Published: March 01, 2022
Regulation of closely juxtaposed proto-oncogene c-fms and HMGXB3 gene expression by mRNA 3' end polymorphism in breast cancer cells.
Journal: RNA (New York, N.Y.)
Published: March 08, 2021
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 18, 2021
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Journal: Nature communications
Published: December 18, 2020
Loss of tubal ciliated cells as a risk for "ovarian" or pelvic serous carcinoma.
Journal: American journal of cancer research
Published: July 20, 2020
Last Updated: 09/26/2026